Editas Medicine (EDIT) Expected to Announce Earnings on Monday

Editas Medicine (NASDAQ:EDIT - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Monday, May 12th. Analysts expect the company to announce earnings of ($0.52) per share and revenue of $0.79 million for the quarter.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.16). The company had revenue of $30.60 million for the quarter, compared to analyst estimates of $37.17 million. Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. During the same quarter in the previous year, the company posted ($0.23) earnings per share. On average, analysts expect Editas Medicine to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Editas Medicine Stock Performance

Shares of Editas Medicine stock traded up $0.08 on Monday, reaching $1.53. 2,333,761 shares of the company were exchanged, compared to its average volume of 2,572,469. The company's 50-day moving average is $1.37 and its two-hundred day moving average is $1.69. The firm has a market cap of $127.66 million, a price-to-earnings ratio of -0.60 and a beta of 2.15. Editas Medicine has a 1-year low of $0.91 and a 1-year high of $6.69.

Wall Street Analyst Weigh In

EDIT has been the topic of a number of research reports. Cantor Fitzgerald upgraded Editas Medicine from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 29th. HC Wainwright assumed coverage on Editas Medicine in a research report on Monday, April 28th. They issued a "buy" rating and a $3.00 target price on the stock. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, two have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $5.73.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.